Quebec biopharmaceutical Medicago and U.K. drugmaker GlaxoSmithKline GSK, +1.48% GSK, +1.35% announced positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects. The overall vaccine efficacy rate against all variants of SARS-COV-2 was 71%. The vaccine candidate demonstrated efficacy of 75.3% against COVID-19 of any severity for the globally dominant Delta variant, while the omicron variant was not circulating during the study. During the study, no related serious adverse events were reported and reactogenicity was generally mild to moderate and transient, the companies said. Medicago, owned by a unit of Mitsubishi Chemical 4188, +0.50%, will imminently seek regulatory approval from Health Canada as part of its rolling submission.
This article was originally published by Marketwatch.com. Read the original article here.
